
[BEGIN TABLE]
 Filed by the Registrant ☒   Filed by a Party other than the Registrant  o  
[END TABLE]
[BEGIN TABLE]
  o   Preliminary Proxy Statement o   Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  
 ☒   Definitive Proxy Statement o   Definitive Additional Materials o   Soliciting Material Pursuant to § 240.14a-12  
[END TABLE]
[BEGIN TABLE]
 ☒   No fee required.  
  o   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.  
     (1)   Title of each class of securities to which transaction applies:  
     (2)   Aggregate number of securities to which transaction applies:  
     (3)   Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):  
     (4)   Proposed maximum aggregate value of transaction:  
     (5)   Total fee paid:  
  o   Fee paid previously with preliminary materials:  
  o   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.  
     (1)   Amount previously paid:  
     (2)   Form, Schedule or Registration Statement No.:   
     (3)   Filing Party:   
     (4)   Date Filed:  
[END TABLE]
[BEGIN TABLE]
     By Order of the Board of Directors  
     David B. Thomson  
     Executive Vice President, General Counsel and Secretary  
[END TABLE]
    5
[BEGIN TABLE]
 Name   Age   Position Held With the Company  
 Kent Kresa(1)(2)   81   Chairman of the Board of Directors  
 Michael E. Castagna, Pharm.D.    42   Chief Executive Officer and Director  
 Ronald J. Consiglio(2)(3)    75   Director  
 Michael A. Friedman, M.D.(1)(2)    75   Director  
 Christine Mundkur(3)    50   Director   
 Henry L. Nordhoff(3)    77   Director  
 James S. Shannon, M.D., MRCP (UK)(1)    62   Director  
[END TABLE]
         15
[BEGIN TABLE]
  2018 2017 
Audit Fees(1) $ 1,132,475   $ 1,143,258   
Tax Fees(2)   183,625     101,208   
Total Fees $ 1,316,100   $ 1,244,466   
[END TABLE]
 17
[BEGIN TABLE]
  Beneficial Ownership 
Name and Address of Beneficial Owner Number of Shares Percent of Total 
Greater than 5% Stockholders              
The Mann Group LLC(1)   19,674,442     9.90% 
12744 San Fernando Road              
Sylmar, CA 91342              
The Alfred E. Mann Living Trust(2)   19,859,000     9.99% 
12744 San Fernando Road              
Sylmar, CA 91342              
Named Executive Officers and Directors              
Michael E. Castagna, Pharm.D.(3)   232,468       * 
Steven B. Binder(4)   3,629       * 
David M. Kendall, M.D.(5)   60,353       * 
James P. McCauley, Jr.(6)   50,165       * 
David B. Thomson, Ph.D., J.D.(7)   383,942       * 
Ronald J. Consiglio(8)   126,511       * 
Michael A. Friedman(9)   81,389       * 
Kent Kresa(10)   283,231       * 
David H. MacCallum(11)   80,819       * 
Christine Mundkur(12)   —       * 
Henry L. Nordhoff(13)   77,595       * 
James S. Shannon(14)   49,750       * 
All current executive officers and directors as a group (17 persons)(15)   1,918,492     1.02% 
[END TABLE]
 19
[BEGIN TABLE]
 Name   Age   Position(s)  
 Michael E. Castagna, Pharm.D.    42   Chief Executive Officer and Director  
 Steven B. Binder    56   Chief Financial Officer  
 Courtney Barton    36   Chief Compliance and Privacy Officer  
 Elizabeth G. Ingram    53   Chief Marketing Officer  
 David M. Kendall, M.D.    57   Chief Medical Officer  
 Joseph Kocinsky    55   Chief Technology Officer  
 James P. McCauley, Jr.    54   Chief Commercial Officer  
 David B. Thomson, Ph.D., J.D.    52   Executive Vice President, General Counsel and Secretary  
 Stuart A. Tross, Ph.D.    52   Chief People and Workplace Officer  
 Rosabel R. Alinaya    58   Senior Vice President, Investor Relations and Treasury  
[END TABLE]
 21
[BEGIN TABLE]
Name Fees Earned or Paid in Cash ($) Option Awards ($)(1) Restricted Stock Units ($)(2) Total ($) 
Ronald J. Consiglio   80,000     —     124,532     204,532   
Michael A. Friedman, M.D.   67,500     —     124,532     192,032   
Kent Kresa   107,500     —     124,532     232,032   
David H. MacCallum   60,000     —     124,532     184,532   
Christine Mundkur(3)   —     —     —     —   
Henry L. Nordhoff   60,000     —     124,532     184,532   
James S. Shannon   57,500     —     124,532     182,032   
[END TABLE]
   25
[BEGIN TABLE]
 Arena Pharmaceuticals Inc.   Macrogenics Inc.  
 ACADIA Pharmaceuticals Inc.   Momenta Pharmaceuticals  
 Acceleron Pharma Inc.   Newlink Genetics Corp  
 Intersect ENT Inc.   Rigel Pharmaceuticals Inc.  
 Lexicon Pharmaceuticals Inc.    Vanda Pharmaceuticals Inc.  
[END TABLE]
[BEGIN TABLE]
 Arena Pharmaceuticals Inc.   Macrogenics Inc.  
 Acceleron Pharma Inc.   Momenta Pharmaceuticals  
 Dynavax Technologies Inc.   Rigel Pharmaceuticals Inc.  
 Intersect Ent Inc.   Seres Therapeutics, Inc.  
 Lexicon Pharmaceuticals Inc.   Vanda Pharmaceuticals Inc.  
[END TABLE]
[BEGIN TABLE]
Name and Principal Position Year Salary ($)(1) Bonus ($)(2) Restricted Stock Awards ($)(3) Option Awards ($)(3) Non-Equity Incentive Plan Compensation ($)(4) All Other Compensation ($)(5) Total ($) 
Michael E. Castagna, Pharm.D. 2018   500,000     20,000     —     833,040     150,000     5,701 (7)    1,508,741   
Chief Executive Officer  2017   458,718     —     —     606,160     247,708     20,648     1,333,234   
  2016   315,385     —     72,800     1,209,572     144,615     13,028     1,755,400   
Steven B. Binder 2018   400,000     —     —     333,840     100,000     20,452 (8)    854,292   
Chief Financial Officer  2017   176,923     50,000     —     190,204     79,615     18,581     515,323   
David M. Kendall, M.D.(6) 2018   367,789     50,000     —     461,670     91,947     175,495 (9)    1,146,901   
Chief Medical Officer                                              
James P. McCauley, Jr. 2018   400,000     —     —     333,840     100,000     231,642 (10)    1,065,482   
Chief Commercial Officer                                              
David B. Thomson, Ph.D., J.D. 2018   433,255     20,000     —     333,840     108,314     19,716 (11)    915,125   
General Counsel and Secretary  2017   435,839     —     —     151,076     193,936     36,234     817,085   
  2016   424,760     —     —     767,788     127,428     33,915     1,353,891   
[END TABLE]
[BEGIN TABLE]
Name Grant Date All Other  Stock  Awards:  Number of  Shares of  Stock or  Units (#) All Other  Option  Awards:  Number of  Securities  Underlying  Options (#)(2) Exercise or  Base Price  of Options  Awards  Options  ($/Sh) Grant Date  Fair Value  of Stock  and Option  Awards ($) 
Michael E. Castagna, Pharm.D.   5/16/18     —     534,000     1.91     833,040   
Steven B. Binder   5/16/18     —     214,000     1.91     333,840   
David M. Kendall, M.D.   2/21/18     —     180,100     2.76     378,210   
    5/16/18     —     53,500     1.91     83,460   
James P. McCauley, Jr.   5/16/18     —     214,000     1.91     333,840   
David B. Thomson, Ph.D., J.D.   5/16/18     —     214,000     1.91     333,840   
[END TABLE]
[BEGIN TABLE]
  Option Awards Stock Awards 
Name Number of  Securities  Underlying  Unexercised  Options (#)  Exercisable Number of  Securities  Underlying  Unexercised  Options  (#)  Unexercisable Equity Incentive  Plan Awards:  Number of  Securities  Underlying  Unexercised  Unearned  Options (#) Option  Exercise  Price ($) Option  Expiration  Date Number  of Shares  or Units  of Stock  That  Have  Not  Vested  (#) Market  Value of  Shares or  Units of  Stock  That  Have  Not  Vested  ($) Equity Incentive  Plan Awards:  Number of  Unearned  Shares,  Units or  Other Rights  That Have  Not Vested  (#) Equity Incentive  Plan Awards:  Market or  Payout  Value of  Unearned  Shares,  Units or  Other Rights  That Have  Not Vested  ($) 
Michael E. Castagna, Pharm.D.   48,008     17,832 (1)    —     4.55     3/14/2026     8,000 (2)    8,480     —     —   
    50,000     150,000 (3)    —     4.55     5/18/2026     —     —     —     —   
    37,525     112,575 (4)    —     1.42     5/25/2027     —     —     —     —   
    57,750     173,250 (5)    —     1.52     5/29/2027     —     —     —     —   
    75,604     115,396 (6)    —     1.52     5/29/2027     —     —     —     —   
    —     534,000 (7)    —     1.91     5/16/2028     —     —     —     —   
Steven B. Binder   45,025     135,075 (8)    —     1.47     7/17/2027     —     —     —     —   
    —     214,000 (7)    —     1.91     5/16/2028     —     —     —     —   
David M. Kendall, M.D.   —     180,100 (9)    —     2.76     2/12/2029     —     —     —     —   
    —     53,500 (7)    —     1.91     5/16/2028     —     —     —     —   
James P. McCauley, Jr.   45,025     135,075 (8)    —     1.47     7/17/2027     —     —     —     —   
    —     214,000 (7)    —     1.91     5/16/2028     —     —     —     —   
David B. Thomson, Ph.D., J.D.   12,400 (10)    —     —     29.65     8/19/2020     —     —     —     —   
    12,380 (11)    —     —     19.00     3/2/2021     —     —     —     —   
    14,320 (12)    —     —     12.05     8/17/2021     —     —     —     —   
    4,000 (13)    —     —     8.45     5/17/2022     —     —     —     —   
    12,000 (14)    —     —     8.45     5/17/2022     —     —     —     —   
    15,000 (15)    —     —     11.60     8/16/2022     —     —     —     —   
    72,000 (16)    —     —     34.25     5/23/2023     —     —     —     —   
    10,000 (17)    —     —     29.45     8/22/2023     —     —     —     —   
    8,680 (18)    —     —     35.45     8/20/2024     —     —     —     —   
    12,049 (19)    2,411 (19)    —     19.55     8/26/2025     805 (21)    853     —     —   
    62,177 (20)    25,603 (20)    —     4.60     2/18/2026     —     —     —     —   
    20,000 (3)    60,000 (3)    —     4.55     5/18/2026     —     —     —     —   
    37,525 (4)    112,575 (4)    —     1.42     5/25/2027     —     —     —     —   
    —     214,000 (7)    —     1.91     5/16/2028     —     —     —     —   
[END TABLE]
[BEGIN TABLE]
  Option Awards Stock Awards(1) 
Name Number of  Shares Acquired  on Exercise (#) Value Realized  on Exercise ($) Number of  Shares Acquired  on Vesting (#) Value Realized  on Vesting ($) 
Michael E. Castagna, Pharm.D.   —     —     4,000     10,720   
Steven B. Binder   —     —     —     —   
David M. Kendall, M.D.   —     —     —     —   
James P. McCauley, Jr.   —     —     —     —   
David B. Thomson, Ph.D., J.D.   —     —     1,290     1,440   
[END TABLE]
[BEGIN TABLE]
  Triggering Event 
  Termination  ($) Change in  Control ($)(3) 
Michael E. Castagna Lump sum cash payment   —     1,243,603   
  Continuing health and welfare benefits(1)         39,784   
  Intrinsic value of accelerated unvested stock options(2)   —     —   
  Total   —     1,283,387   
Steven B. Binder Lump sum cash payment   —     808,013   
  Continuing health and welfare benefits(1)         34,175   
  Intrinsic value of accelerated unvested stock options(2)   —     —   
  Total   —     842,188   
David M. Kendall, M.D. Lump sum cash payment   —     685,297   
  Continuing health and welfare benefits(1)         15,601   
  Intrinsic value of accelerated unvested stock options(2)   —     —   
  Total   —     700,898   
James P. McCauley, Jr. Lump sum cash payment         809,744   
  Continuing health and welfare benefits(1)   —     34,544   
  Intrinsic value of accelerated unvested stock options(2)   —     —   
  Total   —     844,288   
David B. Thomson, Ph.D., J.D. Lump sum cash payment   871,984     1,042,666   
  Continuing health and welfare benefits(1)   49,632     49,362   
  Intrinsic value of accelerated unvested stock options(2)   —     —   
  Total   921,346     1,092,028   
[END TABLE]
    39
[BEGIN TABLE]
Plan Category Number of Securities to  be Issued Upon  Exercise of Outstanding  Options, Warrants and  Rights (#)(a) Weighted- Average  Exercise Price  of Outstanding  Options,  Warrants and  Rights ($)(b) Number of Securities  Remaining Available for  Issuance Under Equity  Compensation Plans  (Excluding Securities  Reflected in Column (a)  (#)(c) 
Equity compensation plans approved by security holders   11,667,384     5.75     12,108,773(1)  
Equity compensation plans not approved by security holders(2)   —     —     —   
[END TABLE]
       